{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:24:04Z","timestamp":1791901444693,"version":"4.3.4"},"update-to":[{"DOI":"10.1371\/journal.pmed.1003953","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000}}],"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173584"],"award-info":[{"award-number":["82173584"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013058","name":"Jiangsu Provincial Key Research and Development Program","doi-asserted-by":"publisher","award":["BE2021738"],"award-info":[{"award-number":["BE2021738"]}],"id":[{"id":"10.13039\/501100013058","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Anhui Zhifei Longcom Biopharmaceutical Co., Ltd."}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"\n Background<\/jats:title>\n Heterologous boost vaccination has been proposed as an option to elicit stronger and broader, or longer-lasting immunity. We assessed the safety and immunogenicity of heterologous immunization with a recombinant adenovirus type-5-vectored Coronavirus Disease 2019 (COVID-19) vaccine (Convidecia, hereafter referred to as CV) and a protein-subunit-based COVID-19 vaccine (ZF2001, hereafter referred to as ZF).<\/jats:p>\n <\/jats:sec>\n \n Methods and findings<\/jats:title>\n \n We conducted a randomized, observer-blinded, placebo-controlled trial, in which healthy adults aged 18 years or older, who have received 1 dose of Convidecia, with no history of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, were recruited in Jiangsu, China. Sixty participants were randomly assigned (2:1) to receive either 1 dose of ZF2001 or placebo control (trivalent inactivated influenza vaccine (TIV)) administered at 28 days after priming, and received the third injection with ZF2001 at 5 months, referred to as CV\/ZF\/ZF (D0-D28-M5) and CV\/ZF (D0-M5) regimen, respectively. Sixty participants were randomly assigned (2:1) to receive either 1 dose of ZF2001 or TIV administered at 56 days after priming, and received the third injection with ZF2001 at 6 months, referred to as CV\/ZF\/ZF (D0-D56-M6) and CV\/ZF (D0-M6) regimen, respectively. Participants and investigators were masked to the vaccine received but not to the boosting interval. Primary endpoints were the geometric mean titer (GMT) of neutralizing antibodies against wild-type SARS-CoV-2 and 7-day solicited adverse reactions. The primary analysis was done in the intention-to-treat population. Between April 7, 2021 and May 6, 2021, 120 eligible participants were randomly assigned to receive ZF2001\/ZF2001 (\n n<\/jats:italic>\n = 40) or TIV\/ZF2001 (\n n<\/jats:italic>\n = 20) 28 days and 5 months post priming, and receive ZF2001\/ZF2001 (\n n<\/jats:italic>\n = 40) or TIV\/ZF2001 (\n n<\/jats:italic>\n = 20) 56 days and 6 months post priming. Of them, 7 participants did not receive the third injection with ZF2001. A total of 26 participants (21.7%) reported solicited adverse reactions within 7 days post boost vaccinations, and all the reported adverse reactions were mild, with 13 (32.5%) in CV\/ZF\/ZF (D0-D28-M5) regimen, 7 (35.0%) in CV\/ZF (D0- M5) regimen, 4 (10.0%) in CV\/ZF\/ZF (D0-D56-M6) regimen, and 2 (10.0%) in CV\/ZF (D0-M6) regimen, respectively. At 14 days post first boost, GMTs of neutralizing antibodies in recipients receiving ZF2001 at 28 days and 56 days post priming were 18.7 (95% CI 13.7 to 25.5) and 25.9 (17.0 to 39.3), respectively, with geometric mean ratios of 2.0 (1.2 to 3.5) and 3.4 (1.8 to 6.4) compared to TIV. GMTs at 14 days after second boost of neutralizing antibodies increased to 107.2 (73.7 to 155.8) in CV\/ZF\/ZF (D0-D28-M5) regimen and 141.2 (83.4 to 238.8) in CV\/ZF\/ZF (D0-D56-M6) regimen. Two-dose schedules of CV\/ZF (D0-M5) and CV\/ZF (D0-M6) induced antibody levels comparable with that elicited by 3-dose schedules, with GMTs of 90.5 (45.6, 179.8) and 94.1 (44.0, 200.9), respectively. Study limitations include the absence of vaccine effectiveness in a real-world setting and current lack of immune persistence data.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Heterologous boosting with ZF2001 following primary vaccination with Convidecia is more immunogenic than a single dose of Convidecia and is not associated with safety concerns. These results support flexibility in cooperating viral vectored and recombinant protein vaccines.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n \n Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine;\n ClinicalTrial.gov<\/jats:ext-link>\n NCT04833101<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pmed.1003953","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T13:55:13Z","timestamp":1653573313000},"page":"e1003953","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":39,"title":["Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia\/ZF2001): A randomized, observer-blinded, placebo-controlled trial"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8908-2633","authenticated-orcid":true,"given":"Pengfei","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-1327","authenticated-orcid":true,"given":"Lianpan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1124-8963","authenticated-orcid":true,"given":"Pan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1929-5198","authenticated-orcid":true,"given":"Lairun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3869-615X","authenticated-orcid":true,"given":"George F.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cancan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7033-5151","authenticated-orcid":true,"given":"Jingxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1644-0006","authenticated-orcid":true,"given":"Fengcai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"pmed.1003953.ref001","unstructured":"World Health Organization. Impact of COVID-19 on people\u2019s livelihoods, their health and our food systems. [cited 2022 Feb 7]. Available from: https:\/\/www.who.int\/news\/item\/13-10-2020-impact-of-covid-19-on-people\u2019s-livelihoods-their-health-and-our-food-systems."},{"key":"pmed.1003953.ref002","unstructured":"Our World in Data. Coronavirus (COVID-19) Vaccinations. [cited 2022 Apr 7]. Available from: https:\/\/ourworldindata.org\/covid-vaccinations."},{"issue":"7","key":"pmed.1003953.ref003","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"DS Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"10308","key":"pmed.1003953.ref004","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(21)02046-8","article-title":"Considerations in boosting COVID-19 vaccine immune responses","volume":"398","author":"PR Krause","year":"2021","journal-title":"Lancet"},{"issue":"10309","key":"pmed.1003953.ref005","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"SY Tartof","year":"2021","journal-title":"Lancet"},{"issue":"6578","key":"pmed.1003953.ref006","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1126\/science.abm0620","article-title":"SARS-CoV-2 vaccine protection and deaths among US veterans during 2021","volume":"375","author":"BA Cohn","year":"2022","journal-title":"Science"},{"issue":"10255","key":"pmed.1003953.ref007","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"DY Logunov","year":"2020","journal-title":"Lancet"},{"issue":"10275","key":"pmed.1003953.ref008","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"DY Logunov","year":"2021","journal-title":"Lancet"},{"issue":"22","key":"pmed.1003953.ref009","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"A Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"pmed.1003953.ref010","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"M Scully","year":"2021","journal-title":"N Engl J Med"},{"issue":"17","key":"pmed.1003953.ref011","doi-asserted-by":"crossref","first-page":"651","DOI":"10.15585\/mmwr.mm7017e4","article-title":"Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients\u2014United States, April 2021","volume":"70","author":"JR MacNeil","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pmed.1003953.ref012","unstructured":"Centers for Disease Control and Prevention. COVID-19 Vaccine Booster Shots. [cited 2022 Feb 7]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/booster-shot.html."},{"key":"pmed.1003953.ref013","unstructured":"World Health Organization. Interim recommendations for heterologous COVID-19 vaccine schedules. [cited 2022 Feb 7]. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE-recommendation-heterologous-schedules."},{"issue":"10","key":"pmed.1003953.ref014","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMoa2116747","article-title":"Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming","volume":"386","author":"RSG Sablerolles","year":"2022","journal-title":"N Engl J Med"},{"issue":"10319","key":"pmed.1003953.ref015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(21)02718-5","article-title":"Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial","volume":"399","author":"ASV Stuart","year":"2021","journal-title":"Lancet"},{"issue":"10318","key":"pmed.1003953.ref016","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"APS Munro","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"pmed.1003953.ref017","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"S Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"pmed.1003953.ref018","author":"World Health Organization","year":"2021","journal-title":"WHO International Standard First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human)"},{"key":"pmed.1003953.ref019","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial","author":"F Zhu","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"10240","key":"pmed.1003953.ref020","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"FC Zhu","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"pmed.1003953.ref021","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and Heterologous Covid-19 Booster Vaccinations","volume":"386","author":"RL Atmar","year":"2022","journal-title":"N Engl J Med"},{"key":"pmed.1003953.ref022","volume-title":"Plotkin\u2019s Vaccines","author":"A. Stanley","year":"2018","edition":"7"},{"issue":"9","key":"pmed.1003953.ref023","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMc2119426","article-title":"Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant","volume":"386","author":"X Zhao","year":"2022","journal-title":"N Engl J Med"},{"key":"pmed.1003953.ref024","unstructured":"Heaton PM. Booster dose of Janssen COVID-19 vaccine (Ad26.COV2.S) following primary vaccination. Presentation sliders presented at the meeting of Advisory Committee on Immunization Practices (ACIP); October 21, 2021. [cited 2022 Feb 7]. Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-10-20-21\/03-COVID-Heaton-Douoguih-508.pdf."},{"issue":"10277","key":"pmed.1003953.ref025","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"M Voysey","year":"2021","journal-title":"Lancet"},{"key":"pmed.1003953.ref026","article-title":"Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants","author":"V Servellita","year":"2022","journal-title":"Cell"},{"issue":"69","key":"pmed.1003953.ref027","doi-asserted-by":"crossref","first-page":"eabo2202","DOI":"10.1126\/sciimmunol.abo2202","article-title":"Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients","volume":"7","author":"CH GeurtsvanKessel","year":"2022","journal-title":"Sci Immunol"},{"issue":"1","key":"pmed.1003953.ref028","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41422-021-00590-x","article-title":"Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern","volume":"32","author":"J Ai","year":"2021","journal-title":"Cell Res"},{"issue":"10321","key":"pmed.1003953.ref029","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","article-title":"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial","volume":"399","author":"SA Halperin","year":"2022","journal-title":"Lancet"},{"key":"pmed.1003953.ref030","article-title":"Efficacy and safety of the RBD-Dimer-Based Covid-19 vaccine ZF2001 in adults","author":"L Dai","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"pmed.1003953.ref031","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"S Feng","year":"2021","journal-title":"Nat Med"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1003953","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T13:45:22Z","timestamp":1654868722000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003953"}},"subtitle":[],"editor":[{"given":"James G.","family":"Beeson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003953","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.02.24.22271445","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]}}}